Clinical recognition and treatment of atrial ectopic tachycardia in newborns

Dominik Stambach, Vera Bernet, Urs Bauersfeld

Division of Paediatric Cardiology, University Children’s Hospital Zurich, Switzerland
Division of Neonatology, University Children’s Hospital Zurich, Switzerland

Summary

Questions: Atrial ectopic tachycardia (AET) may be difficult to diagnose in neonates and treatment can be complex especially in case of severe heart failure. This study addresses the clinical recognition and drug therapy of AET in neonates.

Methods: Retrospective chart and database review of neonates diagnosed with AET between 1994 and 2002.

Results: AET was diagnosed in 19 neonates at a median age of 18 days (range 0–64). A paroxysmal AET pattern was seen in 10 and a permanent in 9 patients. Tachycardia in the foetal or neonatal period indicated an arrhythmia in 8 patients while 11 showed non-specific symptoms. Severely depressed ventricular dysfunction was observed in 2 patients necessitating cardiovascular resuscitation in 1. The mean maximum paroxysmal AET rate was 213 bpm (range 178–227). For permanent AET, the median mean heart rate was 169 bpm (153–185) and the mean maximum heart rate was 212 bpm (range 196–274). Antiarrhythmic class Ic and III drugs alone or as combination therapy controlled AET in all 18 treated neonates and ventricular dysfunctions resolved. Proarrhythmic drug side effects were seen in 1 patient under propafenone therapy.

Conclusions: AET in neonates is frequently recognised as paroxysmal or permanent tachycardia. Symptoms are often non-specific even though neonates and infants may develop severe ventricular dysfunction. A high degree of awareness is mandatory for neonatologists, paediatricians and primary care physicians to recognise AET in neonates. Class Ic and III antiarrhythmic drugs are effective in the treatment of neonatal AET. Monitoring for proarrhythmic drug side effects is mandatory.

Key words: atrial ectopic tachycardia; newborn; antiarrhythmic therapy

Introduction

Supraventricular tachycardias (SVT) are observed in paediatric patients with an incidence of 0.1–0.4% [1]. Although atrioventricular reentrant tachycardias are the most frequent mechanism, atrial ectopic tachycardias (AET) account for 5–20% of SVT in the paediatric age group [2, 3]. In AET, an ectopic focus, which can be located somewhere in the atria or great veins, acts as a pacemaker with a rate faster than the sinus node [4, 5]. In contrast to atrioventricular reentrant tachycardias, AET can persist despite atrioventricular block (figure 1).

AET occur in paroxysmal and permanent forms. In the permanent form, Garson et al. showed in a series of 11 children with AET, that 82% developed congestive heart failure [6]. Symptoms of AET may be initially absent, subtle or difficult to recognise especially in neonates. Thus, the diagnosis of AET could be delayed with subsequent development of heart failure. Once recognised, AET has a favourable prognosis in infants with a spontaneous resolution rate of over 90% within the first year of life [7].

Aim of this study was to evaluate clinical findings, which may facilitate timely recognition of AET in neonates and infants, and to assess the efficacy of antiarrhythmic drug therapy in this patient group.
Patients and methods

Patients

We retrospectively analysed clinical data, efficacy of drug therapy, long-term therapy and recurrences of arrhythmias in neonates with AET diagnosed between 1994 and 2002. Infants who demonstrated symptoms in the neonatal period were enrolled in the study. The study was approved by the local ethics committee and written patient consent for data collection obtained.

Diagnostics

AET was diagnosed electrocardiographically as described previously by Koike et al. (table 1) [8]. Standard ECG was made at presentation. Unless patients were haemodynamically unstable, 24-hour-ECG recordings were obtained before drug therapy to facilitate analyses of efficacy and potential proarhythmic effects of antiarrhythmic drug therapy. Minimum, maximum and mean heart rates were obtained from 24-hour-ECG. The maximum heart rate ever recorded in standard ECG or 24-hour-ECG was recorded for paroxysmal AET. A mean heart rate of >150 bpm on 24-hour-ECG was considered abnormal in the absence of sinus tachycardia inducing disease states.

Echocardiography was done before treatment to evaluate ventricular function and cardiac anatomy.

Antiarrhythmic therapy

Antiarrhythmic drug therapy was chosen according to the ventricular function (figure 2). In infants with good ventricular function (EF > 45%) propafenone (150–500 mg/m²/d) as first line, sotalol (2–5 mg/kg/d) or flecainide (3–6 mg/kg/d) as second line and amiodarone (10 mg/kg/d for 10 days, thereafter 5–10 mg/kg/d) as third line drugs were given. Class Ic and class III drug combination therapies were used in case there was insufficient class Ic drug effect observed. Intravenous amiodarone with a 5 mg/kg over one hour loading dose followed by continuous infusion of 10–25 μg/kg/min was given in case of feeding difficulties or in infants with medium to severe cardiac dysfunction with a ventricular ejection fraction below 45%. Intravenous amiodarone was switched to oral amiodarone for a total loading phase of 10 mg/kg for ten days and thereafter reduced to 5–10 mg/kg/d. Amiodarone was used in infants with moderately to severely decreased ventricular function due to its low negative inotropic effect and high efficacy [9]. The treatment protocols were based on the observations by our group [9]. Follow-up was done every three months with standard and 24-hour-ECG. At the age of about one year, antiarrhythmic drug therapy was discontinued if no tachycardia recurrence was noted. Thyroid and liver function tests were done in patients receiving amiodarone at therapy start, hospital discharge and every six months while receiving amiodarone.

Statistics

Descriptive statistics were used as appropriate.

Table 1

Criteria for the diagnosis of AET as described by Koike et al. [8].

| Distinct P-waves with a normal or minimal prolonged PR-Interval |
| Identical P-wave morphology of first and subsequent tachycardia beats |
| Warm-up phenomenon at initiation of tachycardia beats |
| Abnormalities in atrial rate, P-wave-axis or morphology features |
| Observation of second-degree atrioventricular block without interruption of the atrial rhythm |
| Wide variability in tachycardia rate |
| Inability to terminate the tachycardia by programmed stimulation or cardioversion |

Figure 2

Stepwise treatment strategy for AET according to ejection fraction (EF). In brackets are the numbers of patients on that therapy.

Figure 1

Example of a 24-hour ECG tracing showing AET partly with 2:1 block. Arrows with P indicate the P-waves of the ectopic focus.
Results

Diagnostics

A total of 19 infants with neonatal AET were diagnosed. All patients had a structurally normal heart. Clinical data and antiarrhythmic drug therapy are summarised in table 2 and figure 2. Possible heart failure or AET related symptoms were detected in 11 neonates while an isolated increased heart rate in the foetal or neonatal period indicated an arrhythmia in 8 patients.

Of 17 neonates with foetal tachycardia 1 mother received therapy with digoxin and flecainide which lowered foetal heart rate, but finally cesarean section was done at 36th week of gestation. In 2 other cases of foetal tachycardia, caesarean section was done because of maternal indications. Birth weight of all neonates with foetal tachycardia were within normal limits and none showed hydrops foetalis.

Cardiopulmonary resuscitation was required in 1 infant with cardiovascular collapse.

Maximum heart rate recorded for paroxysmal AET was median 213 bpm (range 178–227). For permanent AET, the mean heart rate was median 169 bpm (153–185) and the maximum rate 212 bpm (range 196–274).

Antiarrhythmic therapy

Antiarrhythmic drug therapy was given to 18 infants (table 2 and figure 2). No therapy was required in an infant with only rare and well-tolerated paroxysmal episodes of AET, which were not more relevant than normal daily sinus tachycardias. All patients converted to sinus rhythm on antiarrhythmic drug therapy although rate control cannot be excluded in some neonates with AET P wave morphology similar to the sinus P wave. Ventricular function normalised before hospital discharge in all infants with previously decreased function.

AET was successfully treated with flecainide in one child after propafenone and sotalol failed. Propafenone therapy with 260 mg/m²/d had to be stopped because of QRS widening and atrioventricular block as proarrhythmic side effects in one infant two weeks after starting therapy. In all other patients no relevant drug side effects were noted. Thyroid and liver function tests showed normal values in all patients receiving amiodarone.

Antiarrhythmic drugs were successfully stopped in 14 patients after one year of therapy while 4 patients were still on medication after dosage reductions or transient cessation of antiarrhythmic medications demonstrated recurrences of AET. In one patient radiofrequency catheter ablation was performed successfully at three years of age.

<table>
<thead>
<tr>
<th>Case</th>
<th>Sex</th>
<th>Age at diagnosis (days)</th>
<th>Symptoms</th>
<th>LV-Function</th>
<th>Heart rate in initial ECG</th>
<th>Effective drug combination</th>
<th>Combination therapy with</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 patients with paroxysmal AET:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>M</td>
<td>64</td>
<td>Tachycardia in paediatric office</td>
<td>Normal</td>
<td>173</td>
<td>Propafenone</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>17</td>
<td>Respiratory distress syndrome</td>
<td>Normal</td>
<td>160</td>
<td>Propafenone</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>24</td>
<td>Tachycardia in paediatric office and heart murmur</td>
<td>Normal</td>
<td>148</td>
<td>Propafenone</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>28</td>
<td>Foetal tachycardia and tachycardia in paediatric office</td>
<td>Normal</td>
<td>219</td>
<td>Propafenone</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>54</td>
<td>Heart failure, cardiovascular collapse</td>
<td>↓↓↓</td>
<td>220</td>
<td>Amiodarone iv</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>1</td>
<td>Foetal tachycardia and heart failure</td>
<td>↓↓</td>
<td>227</td>
<td>Amiodarone iv</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>4</td>
<td>Gastroschisis, heart failure, tachycardia</td>
<td>↓</td>
<td>160</td>
<td>Amiodarone iv</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>24</td>
<td>Pale skin</td>
<td>Normal</td>
<td>214</td>
<td>Propafenone</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>3</td>
<td>Foetal and postnatal tachycardia</td>
<td>Normal</td>
<td>200</td>
<td>Propafenone, Sotalol</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>21</td>
<td>Cyanosis while drinking, Tachycardia in paediatric office</td>
<td>Normal</td>
<td>200</td>
<td>Propafenone</td>
<td></td>
</tr>
<tr>
<td>9 patients with permanent AET:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>F</td>
<td>10</td>
<td>Foetal tachycardia, pale skin</td>
<td>Normal</td>
<td>206</td>
<td>Propafenone</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>13</td>
<td>Tachycardia in paediatric office</td>
<td>Normal</td>
<td>183</td>
<td>Propafenone</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>3</td>
<td>Tachycardia in paediatric office, drinking deterioration</td>
<td>Normal</td>
<td>170</td>
<td>Flecainide, Amiodarone</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>14</td>
<td>Foetal tachycardia</td>
<td>↓</td>
<td>150</td>
<td>Sotalol</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>28</td>
<td>Tachycardia in paediatric office, excessive sweating</td>
<td>normal</td>
<td>177</td>
<td>Propafenone</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>21</td>
<td>Tachycardia in pediatric office, edema</td>
<td>↓</td>
<td>188</td>
<td>Propafenone</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>4</td>
<td>Foetal tachycardia</td>
<td>normal</td>
<td>200</td>
<td>Propafenone</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>18</td>
<td>Foetal tachycardia and tachycardia in paediatric office</td>
<td>normal</td>
<td>212</td>
<td>none</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>35</td>
<td>Tachycardia in paediatric office, cyanosis while drinking</td>
<td>normal</td>
<td>175</td>
<td>Propafenone</td>
<td></td>
</tr>
</tbody>
</table>

LV-Function: normal (EF >55%); ↓ (EF 45–55%); ↓↓ (EF 30–45%); ↓↓↓ (EF <30%)

EF = Ejection fraction, iv = intravenous, LV = left ventricular
Discussion

This study focuses on clinical recognition of AET and demonstrates that foetal tachycardias or tachycardias detected at paediatric routine visits are often the first clinical sign of AET. Noteworthy is that more than a third of all patients showed foetal tachycardia. This rate is higher than in the group described by Bauersfeld et al., where 3 out of 19 infants had foetal arrhythmias while the other patients showed signs of congestive heart failure [7]. Tachycardia detection was rather accidental in 3 patients during a routine paediatric visit. Symptoms in 11 neonates were fairly non-specific and demonstrated that a high level of awareness is mandatory to recognise subtle symptoms or an isolated increased heart rate as sign of an underlying AET. However, 2 patients presented with moderate to severe ventricular dysfunction and showed that AET, especially when diagnosed with delay might be a life threatening arrhythmia.

One major problem is the differentiation between AET and sinus tachycardia, which can be caused by various disease states such as infection, anaemia, pain, hypovolaemia, hyperthyreosis, structural heart disease or cardiomyopathy. Garson and Gillette showed that standard and 24-hour-ECG are valuable diagnostic tools to diagnose AET [11, 15]. ECG norm values were published by Davignon et al. 25 years ago [16]. Lately, a task force of the European Society of Cardiology published guidelines for the interpretation of neonatal ECG taking into account the Davignon values [17]. Norm values for standard ECG heart rates from birth to day 7 were defined as 90–166 bpm (mean 129) and from day 7 to 30 as 107–182 bpm (mean 149). For 24-hour-ECG we also had consistent with others, defined a mean heart rate of 130 bpm plus 2 standard deviations which means 150 bpm or higher to be abnormal [18].

As described in other studies class Ic (propafenone, flecainide) and class III (sotalol, amiodarone) antiarrhythmic drugs proved to be effective in all treated patients with an acceptable safety profile [7, 10, 12–14]. However, a class Ic and class III antiarrhythmic drug combination therapy was necessary in two infants. One infant showed two weeks after starting therapy a proarrhythmic propafenone effect with QRS widening and atrioventricular block. The delayed proarrhythmic effect was most likely caused by a slow metabolism in this particular patient. However, this illustrates that careful ECG monitoring during starting therapy and follow-up is mandatory. Furthermore antiarrhythmic drug therapy risks and benefits have to be well balanced.

As a result of successful AET control, decreased ventricular function normalised in all children within weeks. This relatively fast recovery may point to the great remodelling potential of the neonatal and infant myocardium.

Although AET has reportedly a chance of spontaneous resolution of 75% to 95% in the first year of life, resolution was only seen in 73% of our patients [7, 19]. To avoid long-term antiarrhythmic drug therapy, radiofrequency catheter ablation was successfully performed in one child who showed no spontaneous resolution for three years. In case of antiarrhythmic drug failure, catheter ablation would also be a last therapeutic resort for infants with AET.

Limitations of this study are its retrospective design and, similar to other paediatric arrhythmia studies, the relatively small patient number although the study comprises the largest number of neonatal patients with AET.

In conclusion, AET in neonates is frequently recognised as paroxysmal or permanent tachycardia that may already have occurred in the foetus. Although neonates and infants may develop severe ventricular dysfunction or even cardiovascular collapse due to AET, symptoms may be non-specific. Therefore, a high degree of awareness is mandatory for neonatologists, paediatricians and primary care physicians to recognise AET in this age group.

Class Ic and III antiarrhythmic drugs are efficient in the treatment of neonatal AET although careful monitoring for proarrhythmic drug side effects is necessary.

Correspondence:
Urs Bauersfeld, MD
Division of Paediatric Cardiology
University Children’s Hospital
Steinwiesstr. 75
CH-8032 Zurich
Switzerland
E-Mail: urs.bauersfeld@kiwi.uzh.ch
References


The many reasons why you should choose SMW to publish your research

What Swiss Medical Weekly has to offer:

- SMW’s impact factor has been steadily rising. The 2005 impact factor is 1.226.
- Open access to the publication via the Internet, therefore wide audience and impact
- Rapid listing in Medline
- LinkOut-button from PubMed with link to the full text website http://www.smw.ch (direct link from each SMW record in PubMed)
- No-nonsense submission – you submit a single copy of your manuscript by e-mail attachment
- Peer review based on a broad spectrum of international academic referees
- Assistance of our professional statistician for every article with statistical analyses
- Fast peer review, by e-mail exchange with the referees
- Prompt decisions based on weekly conferences of the Editorial Board
- Prompt notification on the status of your manuscript by e-mail
- Professional English copy editing
- No page charges and attractive colour offprints at no extra cost

International Advisory Committee
Prof. K. E. Juhani Airaksinen, Turku, Finland
Prof. Anthony Bayes de Luna, Barcelona, Spain
Prof. Hubert E. Blum, Freiburg, Germany
Prof. Walter E. Haefeli, Heidelberg, Germany
Prof. Nino Kuenzli, Los Angeles, USA
Prof. René Lutter, Amsterdam, The Netherlands
Prof. Claude Martin, Marseille, France
Prof. Josef Patsch, Innsbruck, Austria
Prof. Luigi Tavazzi, Pavia, Italy

We evaluate manuscripts of broad clinical interest from all specialities, including experimental medicine and clinical investigation.

We look forward to receiving your paper!

Guidelines for authors:
http://www.smw.ch/set_authors.html

All manuscripts should be sent in electronic form, to:

EMH Swiss Medical Publishers Ltd.
SMW Editorial Secretariat
Farnsburgerstrasse 8
CH-4132 Muttenz

Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: http://www.smw.ch